Anheuser-Busch InBev SA/N... (BUD)

Philip Morris, Booking Holdings, Anheuser-Busch InBev, Elite Pharmaceuticals and National Research are included in this Analyst Blog.

BUD's premiumization strategy looks good. It is gaining from robust consumer demand for its megabrands.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. 24/7 Wall St. Key Points: The U.S. Treasury faces $9 tril...

BUD's performance metrics are showing great improvements from its 5Y and 10Y averages, underscoring why the oversold status has been unwarranted. This is on top of the robust Beyond Beer and no-alcoho...

Anheuser-Busch InBev NYSE: BUD stock moved sharply higher after its quarterly earnings report. The price action is building on the momentum that's been in place since the beginning of the year.

Anheuser-Busch InBev's 2024 10-K report shows robust revenue growth and margin expansion, highlighting its strong economic moat and competitive advantages. The company's scale and premium brand mix dr...

Investors with an interest in Beverages - Alcohol stocks have likely encountered both Kirin Holdings Co. (KNBWY) and Anheuser-Busch Inbev (BUD). But which of these two stocks is more attractive to val...

BUD's Q4 results reflect the continued global strength of its beer portfolio, with notable growth in Beyond Beer offerings and its above-core brands.